Brief: Nextcure Announces Initiation Of Phase 1B/2 Trial To Evaluate NC410 With Keytruda

NextCure

04/10/2022 21:08

Oct 4 (Reuters) - NextCure Inc  NXTC.O :
    * NEXTCURE ANNOUNCES INITIATION OF PHASE 1B/2 CLINICAL TRIAL
TO
EVALUATE NC410 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN
PATIENTS WITH IMMUNE CHECKPOINT REFRACTORY OR NAÏVE SOLID TUMORS
    * NEXTCURE INC - EXPECTS TO REPORT INITIAL PHASE 1B DATA IN
MID-2023 FOLLOWED BY INITIATION OF PHASE 2 COMPONENT OF STUDY

Source text for Eikon:  ID:nGNX4Vtljd 
Further company coverage:  NXTC.O 
 ((Reuters.Briefs@thomsonreuters.com;))